Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmv Capital Regulatory News (EMVC)

Share Price Information for Emv Capital (EMVC)

Share Price is delayed by 15 minutes
Get Live Data
49.00    0.00 (0.00%)
Bid:
48.00
Ask:
50.00
Spread: 2.00 (4.167%)
Market Cap: £13.70m
EMVC Live PriceLast checked at - London Stock Exchange

Intraday Emv Capital Share Chart

Director/PDMR Shareholding

4 Jun 2025 14:34

RNS Number : 4650L
EMV Capital PLC
04 June 2025
 

EMV Capital plc

 

("EMV Capital" or the "Company")

 

Director/PDMR Shareholding

 

EMV Capital plc (AIM: EMVC), the deeptech and life sciences VC investment group, announces that on 4 June 2025, Dr Ilian Iliev (Chief Executive Officer) and Ed Hooper (Executive Director) purchased in aggregate 52,516 ordinary shares in the capital of EMV Capital plc ("Ordinary Shares") through their respective Self-Invested Personal Pensions.

 

Following such purchases Dr Iliev and Mr Hooper holds Ordinary Shares as summarised below:

 

Name

New Ordinary Shares

Total number of Ordinary Shares

Toal percentage of entire issued Ordinary Shares

Dr Ilian Iliev

24,516

3,885,973

13.99%

Ed Hooper

28,000

330,000

1.19%

 

The information below, set out in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Dr Ilian Iliev

2

Reason for the notification

a)

Position/status

Director

b)

 

Initial notification /Amendment

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

EMV Capital plc

b)

LEI

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

EMVC 5p Ordinary Shares

 

GB00BN4R5Q82

b)

Nature of the transaction 

Purchase of Ordinary Shares into SIPP

c)

 

Price(s) and volume(s)

 

 

Price(s)

 

Volume(s)

£0.4074

24,516 shares

 

d)

 

Aggregated information

 - Aggregated volume

 

 - Price

 

N/a

e)

 

Date of the transaction

4 June 2025

f)

 

Place of the transaction

UK AIM

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Ed Hooper

2

Reason for the notification

a)

Position/status

Director

b)

 

Initial notification /Amendment

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

EMV Capital plc

b)

LEI

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

EMVC 5p Ordinary Shares

 

GB00BN4R5Q82

b)

Nature of the transaction 

Purchase of Ordinary Shares into SIPP

c)

 

Price(s) and volume(s)

 

 

Price(s)

 

Volume(s)

£0.3788

10,528 shares

£0.3788

10,528 shares

£0.399

6,944 shares

 

d)

 

Aggregated information

 - Aggregated volume

 

 - Price

 

 

 

28,000

 

£0.38381

e)

 

Date of the transaction

4 June 2025

f)

 

Place of the transaction

UK AIM

 

# # #

 

For more information, please contact:

EMV Capital plc

via Rosewood

Ilian Iliev, CEO

 

 

Panmure Liberum Limited (NOMAD and Broker)

+44 (0)20 7886 2500

Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

 

Rosewood (Financial PR)

+44 (0)20 7653 8702

John West / Llewellyn Angus / Lily Pearce

 

About EMV Capital plc (EMVC)

EMV Capital plc is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies.

 

With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future; EMV Capital invests in, manages and strengthens early stage IP-rich companies.

 

EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:

 

· capital-efficient investments through Group balance sheet;

· fund management of the Evergreen EIS and Martlet Capital Funds;

· syndicated investments leveraging its network of third-party investors.

 

EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.

 

Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

 

www.emvcapital.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUSOORVOUNRAR
12
Date   Source Headline
22nd May 202612:38 pmRNSPosting of Annual Report and Notice of AGM
21st May 20267:00 amRNS-RAMR Bio: Commercial Update
19th May 20267:01 amRNSFinal Results for the year ended 31 December 2025
19th May 20267:00 amRNSPhantom Carried Interest Scheme
14th May 20267:00 amRNSNotice of Final Results
24th Feb 202612:38 pmRNSTR-1
12th Feb 20267:00 amRNS-RPortfolio Update
2nd Feb 20267:00 amRNSTrading and Portfolio Update
8th Jan 20267:00 amRNSPDMR Dealing
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
19th Dec 20257:00 amRNSDirector/PDMR Dealing
19th Dec 20257:00 amRNSDirector/PDMR Dealing
10th Dec 20257:00 amRNS-RWanda Health: Fundraising and Business Update
8th Dec 20257:00 amRNSShare Issue, PDMR Dealings & Total Voting Rights
4th Dec 20257:00 amRNSTR-1
24th Nov 20257:00 amRNSExpansion of Senior Finance Leadership Team
20th Nov 20257:00 amRNS-RPortfolio Update
30th Sep 20257:00 amRNSInterim Results and Investor Presentation
22nd Sep 20257:00 amRNSAsset Purchase Agreement with Destiny Pharma
18th Sep 20257:00 amRNSNotice of Interim Results
30th Jun 202512:22 pmRNSResult of AGM
30th Jun 20257:00 amRNSOffice move and Related Party Transaction
27th Jun 20257:00 amRNSQ-Bot Limited Fundraising
10th Jun 20251:28 pmRNSTR-1
6th Jun 20253:12 pmRNSNotice of AGM and Annual Report & Accounts
4th Jun 20252:34 pmRNSDirector/PDMR Shareholding
4th Jun 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
14th May 20254:02 pmRNSPDS: Q1 Results and Clinical and Corporate Update
9th May 202510:30 amRNSTR-1
27th Mar 20254:46 pmRNSPDS: Q4 Results and Clinical Programs Update
7th Mar 20254:26 pmRNSPDS: VERSATILE-003 Phase 3 Clinical Trial
27th Feb 20254:30 pmRNSPDS: up to $22mn Registered Direct Offering
5th Feb 20253:24 pmRNSPDS Biotech reaffirms guidance for clinical trial
3rd Feb 20257:00 amRNSProAxsis: Status Update and Proposed Fundraise
6th Jan 20254:42 pmRNSTR-1
31st Dec 20247:05 amRNSGrant of Share Options
31st Dec 20247:00 amRNSQ-Bot Fundraising
12th Dec 20244:49 pmRNSTR-1
9th Dec 20247:00 amRNSWanda Health Fundraising
5th Dec 20247:00 amRNSClose of Fundraising and Result of Retail Offer
3rd Dec 20241:24 pmRNSResult of Subscription
3rd Dec 20247:05 amRNSWRAP Retail Offer
3rd Dec 20247:00 amRNSProposed Subscription and Retail Offer; Update
14th Nov 20243:59 pmRNSReplacement RNS: PDS: Update, 3rd Quarter Results
14th Nov 20243:23 pmRNSPDS: Clinical Programs Update, 3rd Quarter Results
8th Oct 20247:00 amRNSDirector/PDMR Shareholding
3rd Oct 20247:00 amRNSDirector/PDMR Shareholding
2nd Oct 20244:38 pmRNSPDS: 36-Month Overall Survival Rate announcement
30th Sep 20247:00 amRNSInterim Results
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.